Merck to acquire biotech company Prometheus Biosciences for $10.8bn

Merck has agreed to acquire Prometheus Biosciences, a Nasdaq-listed clinical-stage biotechnology company, in an all-cash deal worth around $10.8 billion, in a move to bolster ... Read More